celecoxib has been researched along with Epithelial Neoplasms in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT)." | 7.81 | Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression. ( Li, C; Liu, P; Liu, R; Pang, Y; Xu, X; Zheng, J; Zheng, Q, 2015) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 6.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 5.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| "The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT)." | 3.81 | Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression. ( Li, C; Liu, P; Liu, R; Pang, Y; Xu, X; Zheng, J; Zheng, Q, 2015) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 2.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 1.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, YP | 1 |
| Wang, QY | 1 |
| Li, CH | 1 |
| Li, XW | 1 |
| Liu, R | 1 |
| Zheng, J | 1 |
| Li, C | 1 |
| Pang, Y | 1 |
| Zheng, Q | 1 |
| Xu, X | 1 |
| Liu, P | 1 |
| van Kruchten, M | 1 |
| van der Marel, P | 1 |
| de Munck, L | 2 |
| Hollema, H | 2 |
| Arts, H | 1 |
| Timmer-Bosscha, H | 1 |
| de Vries, E | 1 |
| Hospers, G | 1 |
| Reyners, A | 1 |
| Reyners, AKL | 1 |
| Erdkamp, FLG | 1 |
| Smit, WM | 1 |
| Hoekman, K | 1 |
| Lalisang, RI | 1 |
| de Graaf, H | 1 |
| Wymenga, ANM | 1 |
| Polee, M | 1 |
| van Vugt, MATM | 1 |
| Schaapveld, M | 1 |
| Willemse, PHB | 1 |
| Song, YC | 1 |
| Kim, SH | 1 |
| Juhnn, YS | 1 |
| Song, YS | 1 |
2 trials available for celecoxib and Epithelial Neoplasms
| Article | Year |
|---|---|
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2012 |
3 other studies available for celecoxib and Epithelial Neoplasms
| Article | Year |
|---|---|
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
Topics: Blotting, Western; Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cyclooxyge | 2018 |
Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression.
Topics: Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cell Proliferation; Down-Regu | 2015 |
Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Female; Growth Inhibitors; Humans; Ne | 2007 |